<DOC>
	<DOCNO>NCT00004196</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa-2b may interfere growth cancer cell . PURPOSE : Randomized phase III trial study effectiveness interferon alfa-2b treating patient melanoma early lymph node metastasis .</brief_summary>
	<brief_title>Interferon Alfa-2b Treating Patients With Melanoma Early Lymph Node Metastasis</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy regional lymphadenectomy without adjuvant high-dose interferon alfa-2b disease-free survival overall survival patient invasive cutaneous melanoma early submicroscopic sentinel lymph node metastasis detect histology immunohistochemistry polymerase chain reaction ( PCR ) . - Compare effect lymphadenectomy vs observation disease-free survival overall survival patient submicroscopic sentinel lymph node metastasis detect PCR . - Determine recurrence rate survival patient submicroscopic sentinel lymph node metastasis detect PCR . - Determine positive negative predictive value reverse transcriptase PCR analysis sentinel lymph node peripheral blood identify patient risk recurrence death . OUTLINE : This randomize , multicenter study . Patients randomized portion Protocols A B stratify accord tumor thickness ( 1-2 mm v 3-4 mm v great 4 mm ) tumor ulceration ( yes v ) . All patient undergo wide local tumor excision lymphatic mapping sentinel node biopsy . Patients tumor ambiguous drainage pattern undergo lymphoscintigraphy prior tumor excision . Patients evidence metastatic melanoma sentinel node ( ) routine histology , serial sectioning , immunohistochemistry undergone prior regional lymph node dissection proceed protocol A . - Protocol A : Patients metastasis single sentinel node evidence extracapsular extension metastatic disease nonsentinel nod randomize 1 2 treatment arm . - Arm I : Patients receive adjuvant high-dose interferon alfa-2b IV 5 day week 4 week , subcutaneously 3 time week 48 week . - Arm II : Patients undergo observation . Patients metastases one sentinel node evidence extracapsular extension metastasis nonsentinel node receive adjuvant high-dose interferon alfa-2b arm I . Patients evidence sentinel node ( ) metastases routine histology , serial sectioning , immunohistochemistry negative polymerase chain reaction ( PCR ) analysis observe . - Protocol B : Patients positive sentinel node ( ) PCR analysis randomize one three treatment arm . - Arm I : Patients undergo observation . - Arm II : Patients undergo lymph node dissection . - Arm III : Patients undergo lymph node dissection follow adjuvant high-dose interferon alfa-2b IV 5 day week 4 week . Patients follow every 3 month 2 year , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 3,000 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive cutaneous melanoma Breslow thickness least 1.0 mm Primary site must head , neck , trunk extremity No 90 day since biopsy Protocol A : One sentinel lymph node histologic immunohistochemical evidence metastatic melanoma Prior regional lymph node dissection Protocol B : Sentinel lymph node histologic immunohistochemical evidence metastatic melanoma Sentinel lymph node positive reverse transcriptase polymerase chain reaction No prior wide local excision primary tumor margin great 1.5 cm No primary melanoma involve eye mucous membrane No clinical evidence satellite lesion intransit , regional nodal , distant metastases No second primary invasive melanoma No prior surgery region primary drain nodal basin would disrupt normal lymphatic drainage pattern ( e.g. , skin graft , tissue transfer flap , lymph node dissection ) PATIENT CHARACTERISTICS : Age : 18 70 Performance status : Karnofsky 70100 % Life expectancy : At least 10 year Hematopoietic : WBC least 3,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Platelet count least 70,000/mm^3 Hemoglobin least 10.0 g/dL Hepatic : Bilirubin le 2.0 mg/dL SGOT/SGPT le 3 time upper limit normal ( ULN ) Alkaline phosphatase less 3 time ULN No severe decompensated liver disease ( e.g. , cirrhosis autoimmune hepatitis ) No significant liver disease would preclude study participation Renal : Creatinine normal Cardiovascular : No cardiovascular disease ( e.g. , angina congestive heart failure ) No myocardial infarction within past year No tachyarrhythmias Pulmonary : No severe debilitate pulmonary disease ( e.g. , chronic obstructive pulmonary disease ) Other : No hypersensitivity interferon alfa2b related compound component injection No major depression major psychiatric illness No thyroid disorder thyroid function maintain within normal range medication No autoimmune disease No primary secondary immunodeficiency No severe diabetes mellitus prone ketoacidosis No significant retinal abnormality No evidence infection No malignancy within past 5 year except basal cell squamous cell skin cancer , carcinoma situ cervix , stage I laryngeal cancer No medical condition would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy Chemotherapy : No prior chemotherapy Endocrine therapy : At least 6 month since prior oral parenteral steroid Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics No prior organ transplantation Other : At least 6 month since prior immunosuppressant No concurrent immunosuppressant result prior organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage I melanoma</keyword>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
</DOC>